Related Experiment Video
Updated: Sep 17, 2025

Spontaneous Murine Model of Anaplastic Thyroid Cancer
Published on: February 3, 2023
Somatic mutations in the TG and RELA genes specific for radioiodine-refractory thyroid cancer
Chanan Suprakun1, Pattarin Nuwongsri2, Siraprapa Tongkobpetch3,4
1Division of Nuclear Medicine, Department of Radiology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand. Chanan.s@chula.ac.th.
Abstract:
Radioactive iodine-refractory (RAI-R) thyroid cancer is associated with poor prognosis and limited treatment options. Identifying RAI-R status early in treatment is crucial for optimizing therapy. This study aims to identify genetic variants distinguishing RAI-R from radioiodine-sensitive (RAI-S) thyroid cancers. The study included six RAI-R patients and six age-matched RAI-S controls. DNA from tumor tissues and peripheral leukocytes of RAI-R patients underwent long-read whole-genome sequencing, while tumor DNA from RAI-S patients underwent whole-exome sequencing. RNA and immunohistochemistry (IHC) analyses were performed to assess candidate variants. Among the six RAI-R patients, three showed disease progression. These patients harbored somatic heterozygous variants in the TG gene, including a c.7863-7_7864delTTCTCACinsG variant, an 8,232 bp deletion encompassing exons 33-34, and a missense variant (c.5488 C > T; p.Pro1830Ser). No TG variants were found in RAI-S or non-progressive RAI-R patients. Additionally, one RAI-R patient had a somatic nonsense variant in the RELA gene (c.601 C > T; p.Arg201Ter). qRT-PCR showed lower NIS expression in RAI-R patients with TG or RELA variants, whereas RAI-S patients exhibited higher NIS expression. Somatic TG and RELA variants were identified in RAI-R thyroid cancer. These variants could serve as early biomarkers for identifying RAI-R status, enabling more tailored treatment strategies.
Insights
New genetic variants in TG and RELA genes are linked to radioactive iodine-refractory (RAI-R) thyroid cancer. These findings could help identify RAI-R status early for better treatment strategies.
Area of Science:
- Oncology
- Genetics
- Molecular Biology
Background:
- Radioactive iodine-refractory (RAI-R) thyroid cancer presents a poor prognosis and limited therapeutic avenues.
- Early identification of RAI-R status is critical for effective patient management and treatment optimization.
Purpose of the Study:
- To identify specific genetic variants that differentiate RAI-R thyroid cancer from radioiodine-sensitive (RAI-S) thyroid cancer.
- To explore the potential of these variants as early biomarkers for predicting RAI-R status.
Main Methods:
- Whole-genome and whole-exome sequencing were performed on tumor DNA from RAI-R and RAI-S patients.
- RNA analysis and immunohistochemistry (IHC) were utilized to evaluate candidate genetic variants.
- Quantitative reverse transcription PCR (qRT-PCR) was employed to assess NIS gene expression levels.
Main Results:
- Somatic heterozygous variants in the TG gene were identified in three progressive RAI-R patients.
- A somatic nonsense variant in the RELA gene was found in one RAI-R patient.
- Lower NIS expression was observed in RAI-R patients with TG or RELA variants, contrasting with higher NIS expression in RAI-S patients.
Conclusions:
- Somatic variants in the TG and RELA genes are associated with RAI-R thyroid cancer.
- These genetic variants show potential as early biomarkers for identifying RAI-R status.
- The identification of these variants may facilitate the development of more personalized treatment strategies for thyroid cancer patients.
Related Concept Videos
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Cancer-Critical Genes I: Proto-oncogenes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Synthesis and Regulation of Thyroid Hormones
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Loss of Tumor Suppressor Gene Functions
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...

